Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.30 |
| ▸ | FABP4 | P15090 | 1/20 | 0.30 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599231 | 0.81 | ALDH1A1 (0.31) | — | |
| SCHEMBL5279383 | 0.73 | ARG1 (0.43) | GLA | |
| SCHEMBL7389229 | 0.69 | ALDH1A1 (0.34) | EGLN3MAPK1GLAACEFABP3 | |
| SCHEMBL9740247 | 0.65 | GLA (0.37) | EGLN3ESR1MAPK1GLAFABP3 | |
| SCHEMBL6791494 | 0.65 | GLA (0.39) | EGLN3MAPK1GLAFABP3FABP4 | |
| SCHEMBL7723359 | 0.65 | GLA (0.48) | EGLN3MAPK1GLAACEFABP3 | |
| Hydrochloric Acid SCHEMBL11622681 | 0.64 | GLA (0.40) | EGLN3MAPK1GLAFABP3FABP4 | |
| Water SCHEMBL28143654 | 0.63 | GLA (0.35) | EGLN3MAPK1GLAFABP3FABP4 | |
| Water SCHEMBL28143655 | 0.63 | GLA (0.35) | EGLN3MAPK1GLAFABP3FABP4 | |
| SCHEMBL2113300 | 0.63 | GLA (0.38) | EGLN3MAPK1GLAFABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646383-A4 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7339065-B2 | Design and synthesis of optimized ligands for PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | THE UNIVERSITY OF MISSISSIPPI | 2007-05-03 | — | — | US | disclosed |
| EP-1646383-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | Bethesda Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005009437-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-0752987-B1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | VERTEX PHARMA (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002076177-A2 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6407080-B2 | USED AS RESEARCH TOOLS IN PHARMACOLOGICAL, DIAGNOSTIC STUDIES AND TREATMENT OF DISEASES IN MAMMALS IN WHICH 1L-BETA-PROTEASE ACTIVITY IS IMPLICATED; ANTIINFLAMMATORY AGENT | VERTEX PHARMACEUTICALS INCORPORATED | 2002-06-18 | — | — | US | disclosed |
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-06-14 | — | — | US | disclosed |
| US-6162800-A | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-19 | — | — | US | disclosed |
| US-5670494-A | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1β converting enzyme inhibitors | SANOFT | 1997-09-23 | — | — | US | disclosed |
| EP-0752987-A4 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP INC (US) | 1997-04-09 | — | — | EP | disclosed |
| EP-0752987-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1995026958-A1 | PYRIMIDINYL DERIVATIVES AS INTERLEUKIN INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003750-A1 | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1RN | EGLN3 716/4885ESR1 3869/4885MAPK1 619/4885 |
| US-20070099969-A1 | Design and synthesis of optimized ligands for ppar | PPARD, PPARA, PPARG | EGLN3 2384/4885ESR1 1053/4885MAPK1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.